The "Friedreich
Ataxia Ongoing Global Clinical Trials Analysis and Outlook"
report has been added to ResearchAndMarkets.com's
offering.
Friedreich Ataxia ongoing clinical trials report
provides comprehensive analysis and trends in global Friedreich Ataxia
disease clinical trials. The research work analyzes the ongoing
Friedreich Ataxia clinical trial trends across countries and companies.
The
report focuses on drugs and therapies being evaluated for Friedreich
Ataxia treatment in active clinical development phases including phase
1, phase 2, phase 3 and phase 4 clinical trials. The report also
provides trials information by region, key countries, enrollment,
phases, trial status and sponsor types.
Our experienced
database team dynamically updates the clinical trials data from several
sources including Clinical trial registries, conferences, journals and
company releases etc. Further, data is presented in user friendly manner
to enable readers quick access to Friedreich Ataxia clinical trials.
Scope
of the Report:
- Ongoing Friedreich Ataxia clinical trials across regions
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Friedreich Ataxia
- Both observational and interventional trials analyzed
- Leading companies and universities participating in Friedreich Ataxia clinical trials
Reasons to Buy:
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market
Key Topics Covered:
1 Table of Contents
2
Key Findings, 2018
3 Clinical Trials Trends to 2022
4
Country Level Analysis
5 Company Level Analysis
6
Enrolment Trends to 2022
7 Ongoing Trials- Phase, ID, Title,
Location, Type, Duration, Recruitment Status, Company Details
8
Appendix
For more information about this report visit https://www.researchandmarkets.com/research/7zd4x2/global_friedreich?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180720005151/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Clinical
Trials
